Prostate health market by Disease Indication (Prostatitis, benign prostatic hyperplasia, Prostate cancer, and others), Treatment (Alpha-Blockers, 5 Alpha Reductase, Cytotoxic Agents, PARP Inhibitors, Hormone ADT, and others): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026482 | Pages: 100 | Industry: Biotechnology | Date: Sep 2022 | Type: Global

The market crossed US$ 35.01 billion mark in 2022 and is expected to hit US$ 70.08 billion by 2030, recording a CAGR of 9.1% during the forecast period.

Prostate health market has been significantly growing with the increasing prevalence of prostate cancer

Increasing prevalence of prostate cancer, growing research environment, increased number of grants, funds, and investments for R&D activities for BPH treatment, and rising demand for hormone therapy drugs are some of the major factors driving the growth of the prostate health market. For instance, according to American Cancer Society (ACS), about 1 man in 8 is expected to diagnosed with prostate cancer during his lifetime. About 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40. Thus, with the increasing geriatric population the market is expected to witness a significant growth during the forecast period. The prostate cancer segment is expected to pace up with the growing geriatric population. Further, other segment such as treatment is also expected to gain traction during the forecasted year.

Within the report, the prostate health market is segmented into disease indication, treatment, and geography. By disease indication, the market is further segmented into prostatitis, benign prostatic hyperplasia, prostate cancer, and others. On the basis of treatment, the market is segmented into alpha-blockers, 5 alpha reductase, cytotoxic agents, PARP inhibitors, hormone ADT, and others. Geographically, the prostate health market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Development of new technologies empowered the growth of futuristic innovations.

New advancements in technologies and development of novel therapies such as prostate-specific membrane antigen (PSMA) targeted therapy is likely to contribute to market growth. For instance, PSMA is a potential biomarker for prostate cancer and is present in high concentration on the surface of cancerous cells in prostate gland. Further, results of PSMA-targeted radionuclide therapy have also verified its potential as an ideal target for diagnosing and treating prostate cancer.

Increasing product approvals is one of the major factors accelerating the market growth.

The increasing number of drug and therapy approvals for the treatment of prostate cancer and BPH is expected to contribute to prostate health market. For instance, in March 2022, Novartis received the USFDA approval for Pluvicto (targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer). The pharmaceutical industry is also encouraging the research and development of new therapies for the treatment of prostate cancer.


Recent strategic developments in prostate health market

The prostate health market has undergone several significant developments, and a few of these have been mentioned below:

  • In December 2021, The US Food and Drug Administration (FDA) has approved Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 to treat metastatic castration-resistant prostate cancer (mCRPC).
  • In January 2021, Myovant announced its partnership with Pfizer to introduce its drug Orgovyx (relugolix).
  • In June 2021, Novartis announced that the FDA had approved 177Lu-PSMA-617, experimental device therapy to treat metastatic castration-resistant prostate cancer (mCRPC).
  • In 2020, Asahi Kasei Pharma obtained new drug approval in China for Flivas (naftopidil), an agent for treating dysuria associated with BPH.

The prostate health market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Novartis; GlaxoSmithKline plc.; Eli Lilly and Company; Astellas Pharma Inc.; Pfizer Inc.; Merck & Co., Inc.; Abbott; AstraZeneca PLC; Bayer AG; and Bristol-Myers Squibb Co. are among the prominent players operating in the market.

Target audience for the report:

  • API manufacturers
  • Pharmaceutical companies
  • Biopharmaceutical Companies
  • Packaging providers
  • Drug-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Disease Indication:
    • Prostatitis
    • Benign prostatic hyperplasia (BPH)
    • Prostate cancer
    • Others


  • Treatment:
    • Alpha-Blockers
    • 5 Alpha Reductase
    • Cytotoxic Agents
    • PARP Inhibitors
    • Hormone ADT
    • Others


  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa


  • Companies profiled:
    • Novartis
    • GlaxoSmithKline plc.
    • Eli Lilly and Company
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Abbott
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Co.

Companies profiled:
- Novartis
- GlaxoSmithKline plc.
- Eli Lilly and Company
- Astellas Pharma Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Abbott
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Co.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Purchase Options
Single User License
Site License
Enterprise License